Kirsten Hogg
(03) 9345 2805
Seeking participants with BRCA gene mutation
A study of the effects of denosumab on normal breast tissue for BRCA gene carriers
Denosumab is approved for use in osteoporosis. Laboratory research has identified other potential effects, including possibly slowing or stopping breast cell growth. The BRCA-D trial aims to investigate the effects of denosumab on normal breast tissue in patients with BRCA 1 or 2 mutations and to determine if the drug has potential to prevent breast cancer. Breast tissue will be obtained and evaluated before and after the denosumab injections.
Recruitment status: Ongoing
Who can take part
- People with documented BRCA1 or BRCA2 mutation
- Normal blood calcium levels
- Participants must agree to take Calcium and Vitamin D supplementation
- Participants with reproductive potential must be willing to use acceptable methods of effective contraception (with the exception of hormonal contraception)
What is involved for you
- Breast MRI and breast biopsy
- 3-5 clinic visits for physical examination and blood tests
- Injection of denosumab every 28 days
- Note that this is a pilot drug study and does not fall under the phase 1-4 categories
For more details
More information about this study is available via the TransBCR website.
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
For more information
Quote reference number
2014.015